Litigation Spotlight Update: The Infliximab (Remicade®) Litigation
The Strict Limits of 3 U.S.C. § 121’s Safe Harbor Provision (And the Intersection of Two Blogs)q
Leave No Stone Unturned – Microsoft Corp. v. Parallel Networks
The Federal Circuit Affirms: The Apotex Filgrastim (Neupogen®) and Pegfilgrastim (Neulasta®) Litigation
Litigation Spotlight Update: The Saga Continues: The Infliximab (Remicade®) Litigation
Cascades Projection v. Epson – Questioning the Constitutionality of IPRs
The Bounds of Procedural Due Process – Intellectual Ventures II LLC v. Ericsson, Inc.
The Patent Dance Goes on for Genentech and Amgen Over Bevacizumab (Avastin®)
